Wealth Enhancement Advisory Services LLC Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Wealth Enhancement Advisory Services LLC boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 55.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,449 shares of the medical equipment provider’s stock after purchasing an additional 2,645 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Hologic were worth $607,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its holdings in Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after acquiring an additional 450,190 shares during the period. Black Creek Investment Management Inc. increased its holdings in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after purchasing an additional 87,176 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $79.29 on Friday. The stock has a market cap of $18.42 billion, a P/E ratio of 23.81, a PEG ratio of 3.03 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The business’s 50-day moving average price is $81.02 and its two-hundred day moving average price is $78.13. Hologic, Inc. has a twelve month low of $66.93 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the business earned $0.89 earnings per share. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Hologic, Inc. will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HOLX shares. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday. Evercore ISI raised their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Mizuho reduced their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.